NCT04335123View on ClinicalTrials.gov

Study of Open Label Losartan in COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 4, 2020

Primary Completion Date

June 21, 2020

Study Completion Date

August 17, 2020

Conditions
COVID-19
Interventions
DRUG

Losartan

25 mg QD from day 0 to day 3. Dose escalation to 50 mg QD until study completion

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

All Listed Sponsors
lead

University of Kansas Medical Center

OTHER

NCT04335123 - Study of Open Label Losartan in COVID-19 | Biotech Hunter | Biotech Hunter